MedTrace Logo

Rivaroxaban in Endovenous Laser Ablation With and Without Miniphlebectomy

NCT02584842 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2015-10-23

No results posted yet for this study

Summary

The purpose of this study is to determine retrospectively if the application of rivaroxaban after endovenous laser ablation with and without miniphlebectomy is safe and if it lowers the risk of venous thrombosis.

Conditions

  • Varicose Veins
  • Venous Thrombosis
  • Thromboembolism
  • Bleeding

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Luca Spinedi, MD, Dr. · University Hospital, Basel, Switzerland

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02584842 on ClinicalTrials.gov